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The	  article	  analyses	  the	  involvement	  of	  pharmaceutical	  companies	  from	  emerging	  markets	  in	  global	  
health	  governance.	  It	  finds	  that	  they	  play	  a	  central	  role	  as	  low-­‐cost	  suppliers	  of	  medicines	  and	  
vaccines	  and,	  increasingly,	  new	  technologies.	  In	  so	  doing,	  pharmaceutical	  companies	  from	  emerging	  
markets	  have	  facilitated	  the	  implementation	  of	  a	  key	  goal	  of	  global	  health	  policy:	  widening	  access	  to	  
pharmaceutical	  treatment	  and	  prevention.	  Yet,	  looking	  closer	  at	  the	  political	  economy	  underlying	  
their	  involvement,	  the	  article	  exposes	  a	  tension	  between	  this	  policy	  goal	  and	  the	  political	  economy	  
of	  pharmaceutical	  development	  and	  production.	  By	  declaring	  access	  to	  pharmaceuticals	  a	  goal	  of	  
global	  health	  policy,	  governments	  and	  global	  health	  partnerships	  have	  made	  themselves	  dependent	  
on	  pharmaceutical	  companies	  to	  supply	  them.	  Moreover,	  to	  provide	  pharmaceutical	  treatment	  and	  
prevention	  at	  the	  global	  level,	  they	  depend	  on	  companies	  to	  supply	  medicines	  and	  vaccines	  at	  
extremely	  low	  prices.	  Yet,	  the	  development	  and	  production	  of	  pharmaceuticals	  is	  organized	  around	  
commercial	  incentives	  that	  are	  at	  odds	  with	  the	  prices	  required.	  The	  increasing	  involvement	  of	  low-­‐
cost	  suppliers	  from	  emerging	  markets	  mitigates	  this	  tension	  in	  the	  short	  run.	  In	  the	  long	  run,	  this	  
tension	  endangers	  the	  sustainability	  of	  global	  access	  policies	  and	  may	  even	  undermine	  some	  of	  the	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Introduction	  
	  
The	  role	  of	  emerging	  market	  countries	  in	  global	  health	  governance	  has	  attracted	  increasing	  scholarly	  
attention.	  Studies	  have	  investigated	  the	  influence	  of	  Brazil,	  Russia,	  India,	  China	  and	  South	  Africa	  
(BRICS)	  on	  reforms	  in	  the	  World	  Health	  Organization	  (WHO)i,	  discussed	  whether	  the	  rise	  of	  the	  BRICS	  
is	  leading	  to	  a	  paradigm	  shift	  in	  global	  healthii,	  and	  assessed	  the	  potential	  of	  coalitions	  among	  these	  
countries	  to	  shape	  the	  global	  politics	  of	  access	  to	  medicinesiii.	  In	  this	  literature	  –	  as	  in	  the	  wider	  
International	  Relations	  scholarship	  on	  the	  rise	  of	  the	  BRICSiv	  –	  the	  focus	  has	  almost	  exclusively	  been	  
on	  how	  BRICS	  states	  shape	  world	  politics.	  Little	  attention	  has	  been	  paid	  to	  the	  question	  how	  the	  rise	  
of	  companies	  from	  these	  and	  other	  emerging	  markets	  has	  affected	  global	  political	  dynamics.	  This	  is	  
surprising	  not	  only	  because	  the	  importance	  of	  business	  in	  global	  politics	  is	  now	  widely	  recognisedv,	  
but	  also	  because	  the	  rise	  of	  the	  BRICS	  is	  driven	  largely	  by	  the	  spectacular	  growth	  of	  their	  economies	  
and	  share	  in	  world	  trade,	  both	  of	  which	  is	  carried	  by	  companies	  from	  these	  countries.	  
	  
The	  impact	  that	  companies	  from	  emerging	  markets	  can	  have	  on	  global	  health	  politics	  has	  been	  
illustrated	  with	  regard	  to	  the	  global	  response	  to	  the	  HIV/AIDS	  pandemicvi.	  For	  many	  years,	  the	  
international	  community	  tried	  to	  address	  the	  spiralling	  HIV/AIDS	  pandemic	  in	  low-­‐	  and	  middle-­‐
income	  countries	  through	  improved	  technical	  coordination	  and	  prevention.	  Anti-­‐retroviral	  medicines	  
(ARVs)	  were	  available	  to	  patients	  in	  high-­‐income	  countries,	  but	  donors	  rejected	  the	  idea	  of	  
subsidising	  treatment	  in	  low-­‐	  and	  middle-­‐income	  countries	  because	  of	  the	  high	  costs	  of	  medicinesvii.	  
In	  the	  early	  2000s,	  however,	  a	  policy	  change	  occurred,	  and	  in	  2005,	  G8	  leaders	  endorsed	  the	  goal	  of	  
providing	  “as	  close	  as	  possible	  to	  universal	  access	  to	  treatment	  for	  AIDS	  by	  2010”viii.	  An	  important	  
factor	  for	  the	  change	  of	  heart	  among	  donors	  was	  the	  emergence	  of	  pharmaceutical	  companies	  from	  
middle-­‐income	  countries	  on	  the	  scene.	  They	  helped	  bring	  the	  price	  of	  ARVs	  down	  from	  
approximately	  US$	  10,000	  to	  less	  than	  US$	  150ix,	  which	  made	  large	  scale	  subsidies	  and,	  hence,	  the	  
policy	  goal	  to	  provide	  universal	  access	  possiblex.	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Since	  then,	  widening	  access	  to	  pharmaceuticals	  has	  become	  a	  key	  policy	  goal	  of	  global	  health	  
governance	  not	  only	  with	  regard	  to	  HIV/AIDS	  but	  also	  with	  regard	  to	  many	  other	  diseases,	  including	  
malaria,	  tuberculosis,	  and	  neglected	  tropical	  diseases,	  and,	  most	  recently,	  antibiotics.	  This	  has	  had	  a	  
significant	  effect	  on	  the	  institutional	  structure	  of	  global	  health	  governance	  leading	  to	  a	  range	  of	  
public-­‐private	  partnerships	  to	  facilitate	  the	  procurement	  and	  development	  of	  medicines	  and	  
vaccines.	  Global	  health	  partnerships	  are	  now	  a	  key	  feature	  of	  global	  health	  governance,	  including	  
the	  Global	  Fund	  to	  Fight	  AIDS,	  Tuberculosis	  and	  Malaria	  (GFATM),	  the	  GAVI	  Alliance,	  and	  the	  Drugs	  
for	  Neglected	  Diseases	  Initiative	  (DNDi),	  for	  instancexi.	  Access	  policies	  have	  also	  yielded	  some	  
impressive	  results.	  Today,	  approximately	  10	  million	  people	  living	  with	  HIV/AIDS	  in	  low-­‐	  and	  middle-­‐
income	  countries	  receive	  ARVsxii,	  more	  than	  11.2	  million	  people	  have	  been	  treated	  for	  
tuberculosisxiii,	  and	  more	  than	  440	  million	  children	  in	  low-­‐	  and	  middle-­‐income	  countries	  have	  been	  
vaccinated	  against	  diseases	  such	  as	  diphtheria,	  tetanus,	  pertussis,	  hepatitis	  B,	  haemophilius	  
influenzae	  type	  b,	  meningitis,	  polio,	  Japanese	  encephalitis,	  diarrheal	  diseases,	  pneumococcal	  
diseases,	  and,	  most	  recently,	  cervical	  cancerxiv.	  
	  
There	  are	  indications	  that	  companies	  from	  emerging	  markets	  play	  an	  important	  role	  in	  the	  political	  
economy	  underlying	  access	  policies,	  not	  only	  with	  regard	  to	  medicines	  for	  HIV/AIDS.	  Systematic	  
evidence	  is,	  however,	  scarcexv.	  This	  article	  analyses	  the	  involvement	  of	  pharmaceutical	  companies	  
from	  emerging	  markets	  in	  global	  health	  governance	  by	  examining	  their	  contribution	  to	  some	  of	  the	  
largest	  public-­‐private	  partnerships	  for	  financing,	  procurement	  and	  drug	  development.	  It	  shows	  that	  
these	  companies	  are	  key	  suppliers	  and	  increasingly	  important	  partners	  in	  the	  development	  of	  new	  
medicines	  and	  vaccines.	  This	  places	  them	  in	  a	  crucial	  position	  for	  the	  implementation	  of	  what	  has	  
become	  a	  central	  goal	  of	  global	  health	  governance,	  widening	  access	  to	  pharmaceuticals.	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The	  article	  offers	  an	  explanation	  for	  this	  phenomenon	  by	  looking	  at	  both	  policy	  dynamics	  and	  
company	  interests.	  It	  shows	  that	  the	  focus	  on	  access	  to	  pharmaceuticals	  is	  part	  of	  a	  wider	  policy	  
shift	  in	  global	  health	  governance	  from	  technical	  coordination	  and	  prevention	  to	  fighting	  specific	  
diseases.	  This	  shift	  has	  moved	  access	  to	  pharmaceutical	  treatment	  and	  prevention	  into	  the	  centre	  of	  
global	  health	  policy.	  Drawing	  on	  literature	  from	  medical	  sociology	  and	  health	  security,	  the	  article	  
uses	  the	  concept	  of	  ‘pharmaceuticalization’	  to	  capture	  this	  phenomenon.	  Importantly,	  it	  argues	  that	  
the	  pharmaceuticalization	  of	  global	  health	  governance	  has	  created	  a	  dependency	  of	  governments	  
and	  global	  health	  partnerships	  on	  pharmaceutical	  companies.	  In	  particular,	  it	  has	  created	  a	  
dependency	  on	  pharmaceutical	  companies	  that	  can	  supply	  at	  extremely	  low	  prices	  because	  the	  
ability	  to	  scale	  up	  access	  policies	  and	  achieve	  ‘universal’	  access	  depends	  on	  the	  price	  that	  
governments	  and	  global	  health	  partnerships	  have	  to	  pay	  for	  medicines	  and	  vaccines.	  It	  is	  this	  price	  
pressure	  that	  has	  led	  many	  global	  health	  partnerships	  to	  turn	  to	  pharmaceutical	  companies	  from	  
emerging	  markets	  as	  partners	  in	  global	  health	  governance.	  	  
	  
Drawing	  on	  insights	  from	  the	  International	  Business	  literature,	  the	  article	  shows	  that	  emerging	  
market	  companies	  are	  willing	  to	  supply	  at	  low	  prices	  not	  only	  because	  of	  lower	  production	  costs	  but	  
also	  to	  get	  access	  to	  new	  technologies.	  Yet,	  the	  analysis	  points	  out,	  pharmaceutical	  companies	  from	  
emerging	  markets	  are	  -­‐	  like	  their	  counterparts	  from	  Western	  Europe	  and	  the	  US	  -­‐	  for-­‐profit	  
organisations.	  There	  is	  evidence	  to	  suggest	  that	  the	  continuous	  drive	  for	  lower	  prices	  is	  reducing	  the	  
interests	  also	  of	  emerging	  market	  producers	  to	  supply	  medicines	  and	  vaccines	  at	  the	  prices	  required	  
by	  global	  health	  partnerships.	  	  	  
	  
By	  studying	  the	  role	  of	  emerging	  market	  companies	  in	  global	  health	  governance,	  the	  article	  exposes	  
a	  tension	  between	  the	  policy	  goal	  to	  widen	  access	  to	  pharmaceuticals	  and	  the	  incentives	  for	  
companies	  to	  supply	  them.	  In	  other	  words,	  the	  article	  exposes	  a	  tension	  between	  the	  
pharmaceuticalization	  of	  global	  health	  governance	  and	  the	  political	  economy	  of	  pharmaceutical	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production.	  It	  argues	  that	  this	  tension	  can	  endanger	  the	  sustainability	  of	  global	  access	  policies	  and	  
even	  undermine	  some	  of	  the	  recent	  successes	  in	  expanding	  treatment	  and	  immunization.	  	  
	  
By	  providing	  the	  first	  analysis	  of	  the	  role	  that	  pharmaceutical	  companies	  from	  emerging	  markets	  
play	  in	  global	  health	  governance	  the	  article	  contributes	  to	  the	  burgeoning	  research	  on	  the	  political	  
economy	  of	  global	  healthxvi.	  More	  broadly,	  the	  article	  hopes	  to	  fuel	  a	  nascent	  interestxvii	  in	  
International	  Relations	  scholarship	  about	  the	  role	  of	  emerging	  markets	  firms	  in	  world	  politics.	  It	  
underlines	  that	  the	  rise	  of	  the	  BRICS	  and	  other	  emerging	  market	  countries	  brings	  with	  it	  a	  rise	  of	  
companies	  that	  affect	  not	  only	  the	  structure	  and	  workings	  of	  the	  global	  economy	  but	  also	  that	  of	  
global	  politics.	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The	  role	  of	  pharmaceutical	  companies	  from	  emerging	  markets	  in	  global	  health	  governance	  
	  
Before	  turning	  to	  the	  empirical	  analysis	  of	  the	  role	  that	  emerging	  market	  companies	  currently	  play	  in	  
global	  health	  partnerships,	  I	  will	  briefly	  explain	  the	  data	  underlying	  the	  analysis.	  	  Global	  health	  
partnerships	  take	  on	  a	  variety	  of	  functions,	  including	  financing,	  procurement,	  product	  development	  
and	  capacity	  building	  for	  companies	  in	  low-­‐	  and	  middle-­‐income	  countries.	  The	  article	  looks	  at	  the	  
three	  largest	  partnerships	  focusing	  on	  the	  financing	  of	  medicines	  and	  vaccines,	  GFATM,	  Stop	  TB	  
Partnership	  Global	  Drug	  Facility	  (GDF),	  and	  GAVI,	  and	  eight	  partnerships	  working	  on	  the	  
development	  of	  new	  medicines	  and	  vaccines,	  so	  called	  Product	  Development	  Partnerships,	  including	  
Aeras,	  DNDi,	  International	  AIDS	  Vaccine	  Initiative	  (IAVI),	  Infectious	  Disease	  Research	  Institute	  (IDRI),	  
Medicines	  for	  Malaria	  Venture	  (MMV),	  Programme	  for	  Appropriate	  Technology	  in	  Health	  
(PATH)/One	  World	  Health	  (OWH)1,	  Sabin	  Vaccine	  Institute	  (Sabin),	  and	  the	  Global	  Alliance	  for	  TB	  
Drug	  Development	  (TB	  Alliance).	  In	  addition,	  the	  article	  looks	  at	  a	  global	  health	  partnership	  aimed	  at	  
increasing	  the	  capacity	  of	  pharmaceutical	  companies	  from	  low-­‐	  and	  middle-­‐income	  countries	  to	  
manufacture	  vaccines	  for	  pandemic	  influenza,	  the	  WHO	  Global	  Action	  Plan	  for	  Influenza	  Vaccines	  
(GAP).	  The	  selection	  of	  global	  health	  partnerships	  is	  based	  on	  two	  considerations:	  1)	  their	  size,	  which	  
is	  considered	  an	  indicator	  of	  their	  impact	  on	  global	  health2	  and	  2)	  the	  availability	  of	  data	  about	  the	  
corporate	  partners	  they	  work	  with.	  	  
	  
Table	  1:	  Global	  health	  partnerships	  included	  in	  this	  study	  
Abbreviation	   Name	  
Aeras	   Aeras	  
DNDi	   Drugs	  for	  Neglected	  Disease	  Partnership	  
IAVI	   International	  AIDS	  Vaccine	  Initiative	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  PATH	  and	  OWH	  merged	  in	  2011.	  
2	  PEPFAR	  is	  a	  similarly	  large	  financing	  mechanism	  as	  GFATM,	  GAVI	  and	  the	  GDF;	  it	  was	  not	  included	  here,	  
however,	  because	  it	  is	  a	  bilateral	  mechanism	  run	  by	  the	  US	  government.	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IDRI	   Infectious	  Disease	  Research	  Institute	  
GFATM	   Global	  Fund	  to	  Fight	  AIDS,	  Tuberculosis	  and	  Malaria	  
GDF	   Stop	  TB	  Partnership	  Global	  Drug	  Facility	  
GAVI	   GAVI	  Alliance	  
MMV	   Medicines	  for	  Malaria	  Venture	  
PATH/OWH	   Programme	  for	  Appropriate	  Technology	  in	  Health/	  One	  World	  Health	  
Sabin	   Sabin	  Vaccine	  Institute	  
TB	  Alliance	   Global	  Alliance	  for	  TB	  Drug	  Development	  
WHO	  GAP	   WHO	  Global	  Action	  Plan	  for	  Influenza	  Vaccines	  	  
	  
	  
Data	  has	  been	  generated	  from	  a	  variety	  of	  sources,	  including	  annual	  reports	  and	  other	  publications	  
made	  available	  by	  the	  global	  health	  partnerships	  and	  by	  individual	  companies;	  the	  Global	  Fund	  Price	  
and	  Quality	  Reporting	  Toolxviii,	  which	  is	  a	  database	  recording	  all	  orders	  that	  GFATM	  has	  placed	  with	  
pharmaceutical	  companies;	  reports	  about	  global	  health	  partnerships	  published	  by	  other	  
organisations,	  such	  as	  Policy	  Cures,	  the	  PDP	  Funders	  Group,	  and	  BioVentures;	  websites	  of	  global	  
health	  partnerships,	  partner	  companies	  and	  international	  organisations;	  and	  articles	  from	  the	  
mainstream	  press	  and	  pharmaceutical	  trade	  publications.	  
	  
Data	  was	  collected	  about	  the	  number	  of	  companies	  from	  emerging	  markets	  that	  individual	  global	  
health	  partnerships	  work	  with	  as	  suppliers,	  R&D	  partners,	  board	  members,	  and	  funders.	  Subsidiaries	  
of	  companies	  where	  the	  parent	  company	  is	  headquartered	  in	  a	  high-­‐income	  country	  were	  not	  
included.	  In	  addition,	  the	  proportion	  of	  companies	  from	  emerging	  markets	  in	  the	  total	  number	  of	  
suppliers	  and	  R&D	  partners	  of	  global	  health	  partnerships	  was	  calculated.	  With	  regard	  to	  data	  on	  
board	  membership,	  the	  proportion	  of	  companies	  from	  emerging	  markets	  in	  the	  total	  number	  of	  
board	  members	  was	  calculated.	  Publicly	  available	  data	  on	  the	  funders	  of	  global	  health	  partnerships	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was	  insufficient	  to	  conduct	  the	  same	  calculation	  for	  the	  proportion	  of	  companies	  from	  emerging	  
markets	  in	  the	  total	  number	  of	  funders.	  
	  
There	  are	  some	  limitations	  to	  the	  data,	  which	  have	  implications	  for	  the	  conclusions	  that	  can	  be	  
drawn	  from	  the	  analysis.	  Firstly,	  data	  on	  the	  volumes	  procured	  from	  individual	  companies	  has	  not	  
been	  collected	  because	  of	  time	  constraints.	  This	  limits	  the	  conclusions	  that	  can	  be	  drawn	  about	  the	  
relative	  importance	  of	  individual	  companies	  as	  suppliers	  of	  medicines	  and	  vaccines.	  Secondly,	  
comprehensive	  data	  on	  the	  number	  of	  relationships	  that	  each	  global	  health	  partnership	  has	  with	  
individual	  companies	  is	  not	  publicly	  available	  because	  of	  confidentiality	  clauses	  covering	  several	  
agreementsxix.	  This	  limits	  the	  conclusions	  that	  can	  be	  drawn	  about	  the	  relative	  importance	  of	  
individual	  companies	  as	  R&D	  partners.	  	  
	  
Emerging	  market	  companies	  as	  suppliers	  of	  medicines	  and	  vaccines	  
Companies	  from	  emerging	  markets	  make	  up	  between	  approximately	  30-­‐50%	  of	  suppliers	  of	  
medicines	  and	  vaccines	  to	  global	  health	  partnershipsxx.	  	  
	  
[insert	  Table	  2]	  
	  
An	  analysis	  of	  the	  orders	  that	  GFATM	  placed	  for	  ARVs	  for	  HIV/AIDS	  in	  the	  period	  January	  2010	  until	  
September	  2013	  shows	  that	  14	  out	  of	  26	  (54%)	  suppliers	  were	  from	  emerging	  markets,	  with	  9	  
companies	  from	  India	  and	  3	  from	  South	  Africa.	  	  A	  different	  study	  found	  that	  between	  2003	  and	  
2008,	  the	  number	  of	  suppliers	  from	  India	  alone	  had	  doubledxxi.	  Similarly,	  12	  out	  of	  22	  (55%)	  
companies	  supplying	  anti-­‐malaria	  drugs	  to	  the	  GFATM	  between	  January	  2010	  and	  September	  2013	  
were	  from	  emerging	  markets,	  9	  of	  which	  were	  from	  India	  and	  2	  from	  China.	  	  
	  
The	  percentage	  is	  slightly	  lower	  with	  regard	  to	  suppliers	  of	  anti-­‐tuberculosis	  medicines	  to	  GFATM.	  11	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out	  of	  33	  (33%)	  companies	  are	  from	  emerging	  markets	  with	  7	  being	  from	  India.	  Similarly,	  the	  
number	  of	  emerging	  markets	  suppliers	  of	  anti-­‐tuberculosis	  medicines	  to	  the	  GDF	  was	  about	  one	  
third	  or	  8	  out	  of	  22	  (36.4%).	  6	  of	  them	  were	  Indian	  companies.	  GAVI	  works	  with	  12	  suppliers	  of	  
vaccines,	  50%	  of	  which	  are	  based	  in	  Africa,	  Asia	  and	  Latin	  America.	  This	  is	  a	  significant	  increase	  from	  
to	  2001	  when	  only	  1	  supplier	  was	  from	  a	  low-­‐income	  country	  (Senegal).	  In	  2014,	  GAVI	  announced	  
that	  it	  was	  extending	  its	  supply	  base	  to	  Chinaxxii.	  	  
	  
Emerging	  market	  companies	  as	  partners	  for	  innovation	  	  
The	  proportion	  of	  emerging	  market	  companies	  among	  corporate	  R&D	  partners	  of	  global	  health	  
partnerships	  is	  not	  as	  high	  as	  among	  their	  suppliers.	  In	  most	  global	  health	  partnerships	  studied	  here	  
it	  varies	  between	  approximately	  10-­‐30%.	  IAVI	  and	  the	  TB	  Alliance	  do	  not	  currently	  have	  R&D	  
collaborations	  with	  emerging	  markets	  companies.	  A	  study	  by	  the	  PDP	  Funders	  Group	  suggests	  that	  
the	  role	  of	  emerging	  markets	  companies	  as	  R&D	  partners	  has	  increased	  significantly	  since	  2007xxiii.	  
	  
IDRI	  lists	  6	  companies	  from	  emerging	  markets	  as	  R&D	  partners	  out	  of	  18	  corporate	  collaborators	  
(33%)	  overall.	  4	  of	  the	  6	  are	  from	  Indiaxxiv.	  MMV	  works	  with	  62	  pharmaceutical	  companies	  on	  R&D,	  7	  
of	  which	  are	  from	  emerging	  markets	  (11%),	  with	  3	  from	  China,	  3	  from	  India	  and	  one	  from	  Russiaxxv.	  	  
According	  to	  Aeras	  annual	  report	  2010,	  3	  out	  of	  a	  total	  of	  15	  industry	  partners	  were	  from	  emerging	  
markets	  (20%),	  with	  1	  from	  China,	  1	  from	  India	  and	  1	  from	  Koreaxxvi.	  In	  2012,	  Aeras	  announced	  it	  had	  
started	  to	  work	  with	  another	  Chinese	  biotechnology	  companyxxvii.	  DNDi	  lists	  5	  companies	  from	  
emerging	  markets	  as	  collaborators	  out	  of	  24	  corporate	  partners	  overall	  (21%);	  2	  of	  them	  are	  from	  
India	  and	  the	  others	  from	  Brazil,	  Colombia	  and	  Tanzaniaxxviii.	  The	  Sabin	  Institute	  lists	  5	  corporate	  R&D	  
partners	  on	  their	  website,	  3	  of	  which	  are	  from	  emerging	  markets	  (60%),	  with	  2	  from	  Brazil	  and	  1	  
from	  Mexicoxxix.	  In	  addition,	  the	  PDP	  Funders	  Group	  reports	  collaboration	  between	  Sabin	  and	  the	  
Chinese	  company	  Frontier	  Biosciencesxxx.	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PATH	  and	  OWH	  are	  affiliated	  institutions	  but	  they	  provide	  separate	  data	  on	  their	  corporate	  R&D	  
partners.	  OWH	  lists	  10	  collaborators	  from	  the	  biopharmaceutical	  industry	  on	  their	  website,	  2	  of	  
which	  (20%)	  are	  based	  in	  Indiaxxxi.	  According	  to	  the	  PDP	  Funders	  Group,	  OWH	  has	  research	  and	  
development	  agreements	  with	  3	  companies	  from	  China	  and	  Indiaxxxii,	  2	  of	  which	  are	  not	  listed	  on	  the	  
OWH	  website.	  PATH	  does	  not	  provide	  an	  overview	  of	  corporate	  R&D	  partners	  but	  a	  look	  at	  PATH’s	  
various	  product	  development	  programmes	  suggests	  that	  emerging	  markets	  companies	  play	  an	  
important	  role.	  According	  to	  John	  Boslego,	  director	  of	  PATH's	  vaccine	  development	  program,	  the	  
organization	  has	  expanded	  collaboration	  with	  emerging	  market	  companies	  in	  recent	  yearsxxxiii.	  In	  the	  
Meningitis	  Vaccine	  Project,	  an	  Indian	  company	  was	  chosen	  as	  the	  manufacturer	  of	  the	  new	  
vaccinexxxiv.	  In	  the	  area	  of	  pneumococcal	  vaccine	  development,	  PATH	  mentions	  6	  collaborators	  from	  
the	  biopharmaceutical	  industry,	  two	  of	  which	  are	  from	  emerging	  markets,	  China	  and	  Indiaxxxv.	  For	  its	  
work	  on	  a	  life	  rotavirus	  vaccine,	  PATH	  mentions	  collaboration	  with	  3	  biopharmaceutical	  companies,	  
all	  of	  which	  are	  from	  China	  and	  Indiaxxxvi.	  PATH	  is	  also	  providing	  technical	  assistance	  to	  a	  Chinese	  
biotechnology	  company	  for	  production	  of	  oral	  polio	  vaccinexxxvii.	  For	  its	  Malaria	  Vaccine	  Partnership,	  
PATH	  lists	  6	  collaborators	  from	  the	  biopharmaceutical	  industry,	  2	  of	  which	  are	  based	  in	  Indiaxxxviii.	  	  
	  
As	  mentioned	  above,	  the	  TB	  Alliance	  does	  not	  currently	  collaborate	  with	  biopharmaceutical	  
companies	  from	  emerging	  markets.	  In	  2007,	  however,	  it	  worked	  with	  the	  Indian	  company	  Lupin	  on	  2	  
drug	  candidates	  for	  tuberculosisxxxix.	  There	  also	  seems	  to	  be	  some	  interest	  in	  the	  growing	  R&D	  
potential	  of	  China.	  In	  2011,	  the	  TB	  Alliance	  signed	  a	  Memorandum	  of	  Understanding	  with	  the	  
International	  Scientific	  Exchange	  Foundation	  of	  China	  to	  establish	  a	  Global	  Health	  R&D	  Centerxl.	  Like	  
the	  TB	  Alliance,	  IAVI	  does	  not	  have	  any	  current	  R&D	  collaborations	  with	  pharmaceutical	  companies	  
from	  emerging	  markets	  xli.	  Yet,	  IAVI’s	  Innovation	  Fund	  has	  provided	  grants	  to	  2	  emerging	  markets	  
companies	  out	  of	  a	  total	  of	  15	  grantees,	  1	  from	  India	  and	  1	  from	  South	  Africaxlii.	  IAVI’s	  Innovation	  
Fund	  was	  established	  to	  harness	  early	  stage	  technology	  in	  AIDS	  vaccine	  development,	  and	  to	  
support	  companies	  in	  proof	  of	  concept	  work,	  which	  is	  important	  to	  attract	  commercial	  investors.	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Capacity	  building	  is	  the	  focus	  of	  the	  WHO	  GAP,	  which	  WHO	  has	  been	  implementing	  in	  collaboration	  
with	  governments	  and	  pharmaceutical	  companies	  since	  2006.	  GAP	  supports	  vaccine	  companies	  in	  
emerging	  markets	  in	  order	  to	  increase	  the	  global	  supply	  of	  influenza	  vaccines.	  Companies	  in	  11	  
countries,	  notably	  Brazil,	  Egypt,	  India,	  Indonesia,	  Iran,	  Korea,	  Mexico,	  Romania,	  Serbia,	  Thailand,	  and	  
Vietnam,	  have	  received	  grants	  so	  far.	  The	  grants	  are	  awarded	  under	  the	  condition	  that,	  in	  the	  case	  
of	  a	  pandemic,	  the	  companies	  sell	  10%	  of	  their	  vaccine	  production	  to	  United	  Nations	  agencies	  for	  
distribution	  in	  low-­‐	  and	  middle-­‐income	  countriesxliii.	  An	  important	  contributor	  to	  the	  GAP	  has	  been	  
the	  US	  Biomedical	  Advanced	  Research	  and	  Development	  Authority	  (BARDA).	  BARDA	  manages	  the	  
procurement	  and	  advanced	  development	  of	  medical	  countermeasures	  for	  chemical,	  biological,	  
radiological,	  and	  nuclear	  agents,	  and	  for	  emerging	  infectious	  diseases	  on	  behalf	  of	  the	  US	  
government.	  Since	  2005,	  the	  US	  has	  provided	  more	  than	  US$	  50	  million	  to	  advance	  influenza	  vaccine	  
development	  in	  low-­‐	  and	  middle-­‐income	  countriesxliv.	  The	  funding	  has	  been	  channelled	  primarily	  
through	  GAP.	  In	  2009,	  BARDA	  established	  a	  US$	  7.9	  million	  cooperative	  agreement	  with	  PATH	  to	  
support	  the	  final	  developmental	  processes	  for	  an	  influenza	  vaccine	  at	  a	  Vietnamese	  manufacturerxlv.	  
The	  considerable	  engagement	  of	  the	  US	  in	  these	  global	  partnerships	  suggests	  that	  the	  government	  
believes	  it	  can	  best	  protect	  its	  population	  from	  future	  influenza	  pandemics	  by	  intercepting	  them	  in	  
the	  countries	  that	  they	  likely	  to	  spread	  in	  first,	  namely	  low-­‐	  and	  middle-­‐income	  countries.	  	  
	  
Emerging	  market	  companies	  as	  board	  members	  of	  global	  health	  partnerships	  
Compared	  to	  their	  role	  as	  suppliers	  and	  R&D	  partners,	  the	  involvement	  of	  emerging	  market	  
companies	  as	  board	  members	  of	  global	  health	  partnerships	  is	  negligiblexlvi.	  For	  this	  study,	  board	  
members	  were	  categorised	  according	  to	  whether	  they	  are	  likely	  to	  represent	  the	  perspectives	  of	  
companies	  from	  emerging	  markets.	  Sometimes,	  board	  members	  are	  selected	  as	  representatives	  of	  a	  
specific	  organisation	  or	  government.	  In	  these	  cases,	  the	  categorization	  did	  not	  present	  any	  difficulty.	  
Sometimes,	  board	  members	  are	  selected	  because	  of	  the	  expertise	  and	  contacts	  they	  have	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accumulated	  in	  the	  course	  of	  their	  careers.	  In	  these	  cases,	  it	  was	  examined	  whether	  they	  had	  
significant	  work	  experience	  in	  companies	  from	  low-­‐	  and	  middle-­‐income	  countries.	  	  
	  
GAVI	  is	  the	  only	  global	  health	  partnership	  analysed	  in	  this	  study	  that	  has	  an	  almost	  equal	  balance	  of	  
corporate	  board	  members	  from	  low-­‐	  and	  middle-­‐income	  countries	  and	  high-­‐income	  countries.	  The	  
organisation	  reserves	  one	  seat	  for	  vaccine	  producers	  from	  low-­‐	  and	  middle-­‐income	  countries	  and	  
one	  for	  producers	  from	  high-­‐income	  countries.	  	  In	  addition,	  there	  are	  2	  independent	  members	  on	  
GAVI’s	  governing	  board	  with	  a	  background	  in	  businesses	  from	  low-­‐	  and	  middle-­‐income	  countries	  and	  
3	  with	  a	  background	  in	  business	  from	  high-­‐income	  countries.	  The	  only	  other	  global	  health	  
partnership	  that	  has	  a	  board	  member	  with	  a	  business	  background	  from	  an	  emerging	  market	  country	  
is	  MMV	  (out	  of	  3	  board	  members	  overall	  with	  a	  business	  background).	  WHO	  GAP	  is	  an	  exception	  as	  
it	  is	  part	  of	  WHO,	  where	  only	  states	  can	  be	  members.	  Also	  GAP’s	  advisory	  board	  has	  only	  members	  
from	  the	  public	  sector.	  	  
	  
Overall	  corporate	  representation	  on	  the	  governing	  boards	  of	  the	  global	  health	  partnerships	  analysed	  
in	  this	  study	  varies	  greatly.	  GDF	  does	  not	  have	  any	  representatives	  from	  the	  business	  sector	  on	  its	  
governing	  board,	  while	  at	  IDRI	  almost	  80%	  of	  board	  members	  (7	  out	  of	  9)	  have	  a	  business	  
background.	  Other	  global	  health	  partnerships	  with	  comparatively	  high	  proportions	  of	  board	  
members	  with	  a	  business	  background	  are	  Aeras	  with	  58%	  and	  the	  TB	  Alliance	  with	  54%.	  On	  IAVI’s	  
governing	  board,	  approximately	  one	  third	  of	  the	  members	  have	  a	  background	  in	  business,	  and	  at	  the	  
governing	  boards	  of	  GAVI	  and	  MMV	  the	  proportion	  is	  approximately	  25%.	  The	  remaining	  global	  
health	  partnerships	  have	  corporate	  representations	  of	  between	  5-­‐15%.	  
	  
Emerging	  market	  companies	  as	  funders	  of	  global	  health	  partnerships	  
The	  picture	  that	  emerges	  with	  regard	  to	  the	  role	  that	  emerging	  market	  companies	  play	  as	  funders	  of	  
global	  health	  partnerships	  is	  similar	  to	  that	  of	  their	  role	  as	  board	  members	  xlvii.	  From	  publicly	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available	  data	  on	  the	  funding	  base	  of	  global	  health	  partnerships	  two	  key	  insights	  emerge.	  First,	  most	  
funding	  seems	  to	  originate	  from	  the	  public	  sector,	  notably	  from	  governments	  in	  North	  America	  and	  
Western	  Europe.	  The	  second	  major	  funder	  is	  the	  Bill	  and	  Melinda	  Gates	  Foundation.	  Funding	  from	  
the	  commercial	  sector	  is	  significantly	  smaller.	  The	  insight	  that	  “the	  private	  sector	  has	  not	  generally	  
met	  the	  initial	  ….	  expectations	  that	  it	  would	  become	  the	  principal	  patron	  of	  these	  partnerships”	  is	  
not	  newxlviii.	  Perhaps	  less	  well	  known	  is	  that	  emerging	  market	  companies	  hardly	  feature	  at	  all	  as	  
funders	  of	  global	  health	  partnerships.	  Among	  the	  global	  health	  partnerships	  analysed	  for	  this	  
research,	  only	  PATH	  names	  companies	  from	  emerging	  markets	  among	  its	  funders.	  Out	  of	  the	  27	  
corporate	  funders	  listed	  by	  PATH,	  1	  is	  a	  biopharmaceutical	  company	  from	  China	  and	  1	  is	  from	  
Indiaxlix.	  
	  
In	  sum,	  pharmaceutical	  companies	  from	  emerging	  markets	  contribute	  significantly	  to	  the	  work	  of	  
global	  health	  partnerships	  as	  suppliers	  and	  R&D	  partners,	  but	  their	  representation	  at	  the	  decision-­‐
making	  level	  is	  weak.	  In	  other	  words,	  pharmaceutical	  companies	  from	  emerging	  markets	  have	  
become	  important	  partners	  in	  the	  implementation	  of	  global	  policies	  to	  widen	  access	  to	  
pharmaceuticals,	  but	  not	  in	  the	  design	  of	  these	  policies.	  	  How	  can	  we	  explain	  this?	  	  
	  
	  
Emerging	  market	  companies:	  Partners	  in	  policy	  implementation	  –	  but	  not	  policy	  design	  
	  
Let	  us	  turn	  first	  to	  the	  rise	  of	  emerging	  market	  companies	  as	  partners	  in	  the	  implementation	  of	  
access	  policies.	  In	  the	  last	  15	  years,	  the	  fight	  against	  specific	  diseases,	  notably	  HIV/AIDS,	  malaria,	  
tuberculosis,	  neglected	  tropical	  diseases,	  and	  pandemic	  influenza,	  has	  emerged	  as	  a	  key	  feature	  of	  
global	  health	  governance.	  With	  it	  has	  come	  a	  focus	  on	  access	  to	  medicines	  and	  vaccines	  as	  a	  key	  
policy	  goal.	  This	  focus	  is	  manifest	  at	  both	  the	  discursive	  and	  the	  institutional	  levels	  of	  global	  health	  
governance.	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With	  regard	  to	  HIV/AIDS,	  the	  Declaration	  of	  Commitment	  on	  HIV/AIDS	  passed	  by	  United	  Nations	  
General	  Assembly	  in	  2001l	  made	  access	  to	  medication	  for	  HIV/AIDS	  and	  the	  development	  of	  a	  HIV	  
vaccine	  a	  key	  goal	  of	  global	  health	  governance.	  The	  Declaration	  recognizes	  “that	  access	  to	  
medication	  in	  the	  context	  of	  pandemics	  such	  as	  HIV/AIDS	  is	  one	  of	  the	  fundamental	  elements	  to	  
achieve	  progressively	  the	  full	  realization	  of	  the	  right	  of	  everyone	  to	  the	  enjoyment	  of	  the	  highest	  
attainable	  standard	  of	  physical	  and	  mental	  health”li.	  In	  addition,	  the	  Declaration	  commits	  to	  
“increase	  investment	  in	  and	  accelerate	  research	  on	  the	  development	  of	  HIV	  vaccines”lii.	  In	  the	  
following	  years,	  a	  consensus	  emerged	  that	  global	  access	  to	  ARV	  treatment	  was	  possibleliii.	  
	  
In	  the	  area	  of	  neglected	  tropical	  diseases,	  a	  roadmap	  by	  WHO	  in	  2012	  identifies	  preventative	  
chemotherapy,	  i.e.	  the	  delivery	  of	  medicines,	  as	  the	  key	  global	  governance	  strategy	  to	  tackle	  these	  
diseasesliv.	  The	  roadmap	  was	  endorsed	  by	  a	  stakeholder	  group	  comprising	  representatives	  of	  
governments,	  the	  pharmaceutical	  industry	  and	  global	  health	  partnerships	  in	  the	  London	  Declaration	  
on	  Neglected	  Tropical	  Diseases.	  The	  first	  three	  of	  the	  Declaration’s	  seven	  commitments	  are	  about	  
access	  to	  medicines.	  The	  Declaration’s	  ‘endorsers’	  commit	  to	  contribute	  to:	  (1)	  “Sustain,	  expand	  and	  
extend	  programmes	  that	  ensure	  the	  necessary	  supply	  of	  drugs	  and	  other	  interventions	  to	  help	  
eradicate	  Guinea	  worm	  disease,	  and	  help	  eliminate	  by	  2020	  lymphatic	  filariasis,	  leprosy,	  sleeping	  
sickness	  …	  and	  blinding	  trachoma”,	  (2)	  “Sustain,	  expand	  and	  extend	  drug	  access	  programmes	  to	  
ensure	  the	  necessary	  supply	  of	  drugs	  and	  other	  interventions	  to	  help	  control	  by	  2020	  
schistosomiasis,	  soil-­‐transmitted	  helminthes,	  Chagas	  disease,	  visceral	  leishmaniasis	  and	  river	  
blindness	  (onchocerciasis)”,	  and	  (3)	  “Advance	  R&D	  through	  partnerships	  and	  provision	  of	  funding	  to	  
find	  next	  generation	  treatments	  and	  interventions	  for	  neglected	  diseases”lv.	  
	  
In	  the	  area	  of	  pandemic	  preparedness,	  the	  EU	  adopted	  a	  Decision	  on	  Serious	  Cross-­‐border	  Threats	  to	  
Health	  in	  2013,	  and	  the	  EU	  Health	  Commissioner	  highlighted,	  “[t]he	  next	  milestone	  for	  health	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security	  under	  this	  legislation	  is	  the	  Joint	  Procurement	  Framework	  Agreement…	  Under	  this	  
agreement,	  Member	  States	  can	  …	  purchase,	  together,	  vaccines	  and	  other	  medical	  countermeasures	  
needed	  to	  fight	  a	  cross	  border	  health	  threat.	  This	  is	  to	  ensure	  that	  all	  Member	  States,	  big	  and	  small,	  
are	  able	  to	  secure	  vaccines	  and	  other	  medicines	  for	  their	  people	  and	  under	  better	  conditions	  than	  in	  
the	  past"lvi.	  Similarly,	  the	  Global	  Action	  Plan	  for	  Influenza	  Vaccines	  of	  the	  World	  Health	  Organization	  
(WHO)	  emphasises	  that	  “[i]nfluenza	  vaccine	  development	  and	  deployment	  are	  critical	  elements	  of	  
pandemic	  influenza	  preparedness”lvii.	  
	  
The	  focus	  on	  widening	  access	  to	  pharmaceuticals	  as	  a	  key	  policy	  goal	  in	  global	  health	  governance	  has	  
become	  manifest	  also	  at	  the	  institutional	  level.	  Many	  organisations	  that	  make	  up	  the	  organisational	  
landscape	  of	  global	  health	  governance	  today	  are	  mandated	  with	  the	  financing,	  procurement	  and	  
development	  of	  pharmaceuticals,	  and	  most	  of	  them	  have	  been	  created	  in	  the	  period	  since	  the	  late	  
1990s.	  	  
	  
Concerted	  global	  efforts	  to	  make	  pharmaceuticals	  more	  widely	  available,	  especially	  in	  low-­‐	  and	  
middle-­‐income	  countries,	  are	  a	  relatively	  new	  phenomenon.	  Prior	  to	  the	  late	  1990s,	  international	  
health	  policies	  focused	  largely	  on	  coordinating	  national	  activities	  for	  the	  events	  of	  infectious	  disease	  
outbreaks	  and	  technical	  guidance	  through	  WHOlviii.	  Perhaps	  the	  most	  important	  precedent	  for	  a	  
global	  mobilisation	  of	  resources	  to	  make	  pharmaceuticals	  widely	  available	  in	  low-­‐	  and	  middle-­‐
income	  countries	  is	  the	  smallpox	  eradication	  programme.	  Between	  1967	  and	  1979,	  vaccines	  were	  
procured	  and	  supplied	  to	  endemic	  countries	  with	  the	  help	  of	  funding	  from	  WHO	  and	  especially	  its	  
largest	  donor	  the	  US.	  
	  
In	  order	  to	  conceptually	  grasp	  the	  recent	  focus	  on	  widening	  access	  to	  pharmaceuticals	  in	  the	  field	  of	  
health	  security	  policy,	  Elbe,	  Roemer-­‐Mahler	  and	  Longlix	  draw	  on	  the	  concept	  of	  
‘pharmaceuticalization’.	  This	  concept	  had	  originally	  been	  developed	  by	  sociologists	  and	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anthropologists	  to	  highlight	  the	  proliferation	  of	  pharmaceuticals	  in	  various	  areas	  of	  social	  lifelx.	  While	  
much	  of	  this	  literature	  focuses	  on	  how	  the	  pharmaceutical	  industry	  drives	  pharmaceuticalization,	  
Elbe	  et	  al.	  apply	  this	  concept	  to	  investigate	  government	  responses	  to	  the	  emergence	  of	  bioterrorism	  
and	  pandemic	  preparedness	  as	  security	  issues.	  The	  authors	  find	  that	  a	  key	  element	  of	  governments’	  
responses	  to	  these	  new	  security	  threats	  has	  been	  the	  development	  of	  medicines	  and	  vaccines	  as	  
‘medical	  countermeasures’	  and	  the	  stockpiling	  of	  existing	  pharmaceuticals.	  Governments,	  they	  
argue,	  are	  important	  drivers	  of	  pharmaceuticalization	  in	  the	  field	  of	  security	  because	  they	  incentivize	  
the	  commercial	  development	  of	  medicines	  and	  vaccines	  by	  providing	  funds,	  granting	  legal	  
protections	  for	  pharmaceutical	  companies,	  introducing	  emergency	  use	  procedures,	  and	  developing	  
systems	  for	  mass	  drug	  administration.	  Such	  incentives	  are	  necessary	  because	  profit-­‐oriented	  
companies	  are	  reluctant	  to	  invest	  in	  products	  that	  may	  never	  be	  needed	  and	  for	  which	  the	  number	  
of	  potential	  buyers	  are	  limited	  to	  a	  few	  governments.	  	  	  
	  
Pharmaceuticalization	  is	  a	  useful	  concept	  for	  the	  present	  study	  because	  it	  helps	  understand	  the	  role	  
that	  pharmaceutical	  companies,	  in	  general,	  and	  emerging	  market	  firms,	  in	  particular,	  have	  obtained	  
in	  global	  health	  governance	  in	  the	  last	  15	  years.	  The	  concept	  highlights	  that	  during	  this	  period	  global	  
health	  has	  become	  strongly	  associated	  with	  the	  pharmaceutical	  treatment	  and	  prevention	  of	  specific	  
diseases.	  It	  points	  out	  that,	  like	  in	  the	  field	  of	  security	  policy,	  the	  recent	  policy	  shift	  has	  been	  
accompanied	  by	  efforts	  to	  widen	  access	  to	  pharmaceuticals	  and	  led	  to	  a	  set	  of	  institutional	  and	  
policy	  responses	  aimed	  at	  incentivising	  their	  development	  and	  production,	  such	  as	  grants,	  
technology	  transfer,	  advance	  market	  commitments,	  and	  pooled	  procurement,	  for	  example.	  Such	  
incentives	  are	  required	  for	  similar	  reasons	  as	  in	  the	  field	  of	  security	  and	  medical	  countermeasures:	  
commercial	  market	  demand	  and,	  hence,	  profit	  margins	  are	  low.	  
	  
The	  concept	  of	  pharmaceuticalization	  highlights	  a	  set	  of	  social	  and	  policy	  dynamics	  that	  promote	  a	  
dependency	  of	  societies	  and	  governments	  on	  pharmaceutical	  products	  and,	  hence,	  companies.	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Pharmaceuticals	  are	  developed	  and	  produced	  largely	  in	  the	  private,	  for-­‐profit	  sector.	  Hence,	  by	  
making	  access	  to	  drugs	  and	  vaccines	  a	  key	  focus	  of	  policy,	  governments	  and	  global	  health	  
partnerships	  have	  made	  themselves	  dependent	  on	  commercially	  operating	  pharmaceutical	  
companies	  to	  enable	  the	  implementation	  of	  this	  policy.	  Moreover,	  in	  order	  to	  be	  able	  to	  provide	  
‘universal’	  access,	  they	  depend	  on	  commercially	  operating	  companies	  to	  supply	  drugs	  and	  vaccines	  
at	  extremely	  low	  prices.	  
	  
Initially,	  governments,	  global	  health	  partnerships	  and	  advocacy	  groups	  had	  approached	  the	  world’s	  
‘big	  pharma’	  companies,	  i.e.	  large	  European	  and	  US	  companies,	  as	  potential	  suppliers	  and	  
development	  partnerslxi.	  These	  companies	  were	  already	  producing	  many	  of	  the	  required	  medicines	  
and	  vaccines	  and	  had	  the	  financial	  and	  technological	  capabilities	  to	  develop	  new	  products.	  Yet,	  big	  
pharma	  companies	  have	  shown	  limited	  interest	  in	  engaging	  in	  global	  health	  partnerships	  and	  
supplying	  medicines	  and	  vaccines	  at	  such	  low	  price	  levelslxii.	  Opportunity	  costs	  are	  high,	  profit	  
margins	  comparatively	  low,	  and	  demand	  is	  often	  difficult	  to	  forecastlxiii.	  There	  is	  some	  evidence	  to	  
suggest	  that	  big	  pharma	  companies	  have	  substantially	  invested	  in	  partnerships	  for	  pharmaceutical	  
development	  particularly	  when	  these	  investments	  could	  be	  linked	  to	  the	  re-­‐purposing	  of	  existing	  
products	  and/or	  the	  opening	  of	  markets	  of	  commercial	  interest	  to	  these	  companieslxiv.	  	  
	  
As	  a	  result,	  governments	  and	  global	  health	  partnerships	  have	  increasingly	  turned	  to	  pharmaceutical	  
companies	  from	  emerging	  markets,	  particularly	  from	  India.	  The	  Indian	  pharmaceutical	  industry	  has	  
long	  been	  the	  fastest	  growing	  pharmaceutical	  industry	  in	  emerging	  markets,	  and	  Indian	  companies	  
had	  early	  on	  developed	  the	  technological	  capabilities	  to	  produce	  many	  of	  the	  medicines	  and	  
vaccines	  required	  by	  global	  health	  partnerships.	  Furthermore,	  until	  2005,	  Indian	  companies	  
operated	  under	  a	  national	  intellectual	  property	  regime	  that	  prevented	  the	  patenting	  of	  
pharmaceutical	  productslxv.	  Finally,	  Indian	  manufacturers	  were	  able	  to	  supply	  at	  prices	  far	  below	  
those	  of	  big	  pharma	  companieslxvi.	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Until	  recently,	  however,	  they	  did	  not	  have	  the	  technological	  and	  financial	  capabilities	  to	  develop	  
new	  products.	  This,	  however,	  is	  changing.	  In	  the	  past	  decade,	  the	  innovative	  capabilities	  of	  
companies	  from	  emerging	  markets,	  particularly	  Brazil,	  China	  and	  India,	  has	  increased	  
substantiallylxvii.	  While	  innovation	  currently	  tends	  to	  be	  incremental	  rather	  than	  for	  entirely	  new	  
moleculeslxviii,	  a	  study	  on	  the	  health	  biotechnology	  sectors	  in	  Brazil,	  China	  and	  India	  identified	  165	  
innovative	  products	  within	  41	  domestic	  firms	  in	  these	  countrieslxix.	  Indian	  companies	  had	  the	  largest	  
share	  of	  innovative	  products	  with	  55%,	  followed	  by	  Chinese	  firms	  with	  29%,	  and	  Brazilian	  firms	  with	  
16%	  of	  the	  total	  number	  of	  products	  identifiedlxx.	  As	  a	  result,	  governments	  and	  global	  health	  
partnerships	  have	  recently	  intensified	  collaboration	  for	  pharmaceutical	  development	  with	  emerging	  
market	  producers.	  
	  
The	  pharmaceuticalization	  of	  global	  health	  governance	  and	  the	  price	  pressure	  resulting	  from	  the	  
goal	  to	  achieve	  ‘universal’	  access	  has	  been	  a	  key	  driving	  force	  for	  governments	  and	  global	  health	  
partnerships	  to	  turn	  to	  pharmaceutical	  companies	  from	  emerging	  markets	  as	  partners	  for	  the	  supply	  
of	  existing	  and	  the	  development	  of	  new	  medicines	  and	  vaccines.	  Yet,	  why	  have	  these	  companies	  
invested	  in	  these	  products	  given	  extremely	  low	  prices	  and	  profit	  margins?	  While	  companies	  from	  
emerging	  markets	  are	  as	  heterogeneous	  as	  companies	  from	  high-­‐income	  countries,	  and	  
generalisations	  are	  therefore	  difficult,	  research	  in	  International	  Business	  has	  found	  that	  companies	  
from	  emerging	  markets	  tend	  to	  differ	  from	  companies	  from	  high-­‐income	  countries	  in	  a	  variety	  of	  
ways	  that	  may	  be	  relevant	  for	  this	  question.	  Scholars	  researching	  the	  internationalisation	  strategies	  
of	  emerging	  markets	  companies	  have	  argued	  that	  their	  investment	  decisions	  can	  often	  be	  explained	  
better	  by	  how	  investments	  contribute	  to	  the	  capability-­‐building	  process	  of	  the	  firm	  than	  by	  
calculations	  of	  short-­‐term	  returnslxxi.	  For	  pharmaceutical	  companies	  from	  emerging	  markets,	  access	  
to	  technology	  and	  expertise	  appears	  to	  be	  of	  particular	  importance	  to	  build	  capabilities	  in	  areas	  such	  
as	  manufacture,	  scale-­‐up,	  regulation	  and	  international	  market	  penetration.	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A	  Brazilian	  biotech	  entrepreneur,	  who	  is	  cited	  by	  Rezaie	  and	  colleagueslxxii	  argued	  that	  “the	  
increasing	  attention	  to	  neglected	  diseases	  by	  prominent	  nonprofits…	  presents	  Brazilian	  SMEs	  [small	  
and	  medium-­‐sized	  companies]	  with	  an	  ideal	  opportunity	  to	  build	  up	  their	  international	  linkages”.	  	  
A	  study	  on	  Indian	  biotech	  companies	  found	  that	  “firms	  are	  interested	  in	  working	  with	  [global	  health	  
partnerships]	  for	  access	  to	  their	  expertise	  and	  resources	  in	  tackling	  global	  health	  issues”lxxiii.	  The	  
Developing	  Countries	  Vaccines	  Manufacturers	  Network	  (DCVMN),	  an	  alliance	  of	  27	  vaccine	  
producers	  from	  14	  low-­‐	  and	  middle-­‐income	  countries,	  names	  “strengthening	  and	  enhancement	  of	  
technology	  …,	  encourage[ing]	  continuation	  of	  research	  and	  development	  efforts	  …,	  and	  
facilitate[ing]	  innovative	  models	  of	  ownership	  of	  health	  related	  intellectual	  property”(Jadhav	  et	  al	  
2009:	  166)	  as	  key	  aims	  of	  the	  Network.	  Indeed,	  when	  DCVMN	  was	  founded	  in	  2001,	  “[i]t	  was	  hoped	  
…that	  GAVI	  would	  support	  the	  Network	  by	  ‘‘push’’	  mechanisms	  such	  as	  facilitating	  access	  to	  
technology”	  (Jadhav	  et	  al	  2008:	  1612).	  With	  regard	  to	  the	  involvement	  of	  the	  Indian	  vaccine	  
company	  Serum	  Institute	  of	  India	  (SII)	  in	  a	  public-­‐private	  partnership	  for	  the	  development	  of	  a	  new	  
meningitis	  vaccine,	  scholars	  have	  found	  that	  access	  to	  a	  new	  technology	  for	  vaccine	  manufacture,	  
namely	  conjugation	  technology,	  was	  key	  for	  SII’s	  decision	  to	  manufacture	  the	  vaccine	  at	  the	  low	  
price	  of	  US$	  0.5	  per	  doselxxiv.	  
	  
Collaboration	  with	  global	  health	  partnerships	  as	  a	  means	  to	  access	  new	  technologies	  is	  a	  strategy	  
that	  has	  been	  observed	  also	  in	  a	  study	  on	  Chengdu	  Biological	  Products,	  a	  large	  public-­‐sector	  vaccine	  
manufacturer	  in	  China.	  The	  authors	  find	  that	  collaboration	  with	  PATH	  “provided	  Chengdu	  with	  much	  
vaccine	  production	  hardware	  and	  software	  that	  they	  would	  not	  ordinarily	  have,	  and	  thus	  gives	  them	  
an	  advantage	  on	  the	  international	  market,	  even	  if	  they	  cannot	  control	  the	  sales	  price”lxxv.	  Scholars	  
researching	  the	  growing	  market	  for	  generic	  ARVs	  for	  HIV/AIDS	  in	  the	  early	  2000s	  found	  that	  the	  
creation	  of	  new	  markets	  by	  humanitarian	  groups,	  such	  as	  Médecins	  Sans	  Frontières,	  and	  
international	  financing	  organizations,	  such	  as	  GFATM,	  was	  an	  important	  factor	  in	  the	  decisions	  of	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Indian	  companies	  to	  supply	  the	  drugs	  at	  low	  prices	  because	  it	  increased	  volumes	  and	  improved	  the	  
predictability	  of	  the	  marketlxxvi.	  	  
	  
Finally,	  research	  suggests	  that	  differences	  in	  ownership	  structure	  between	  companies	  from	  high-­‐
income	  countries	  and	  companies	  from	  emerging	  markets	  may	  influence	  investment	  decisions.	  It	  has	  
been	  argued	  that	  the	  prevalence	  of	  state-­‐	  and	  family-­‐ownership	  among	  emerging	  markets	  
companies	  may	  make	  decisions	  in	  favor	  of	  long-­‐term	  and	  less	  secure	  investments	  more	  likely	  than	  
the	  shareholder	  model	  of	  corporate	  governance	  and	  financing	  that	  is	  prevalent	  among	  most	  big	  
pharmaceutical	  companies	  from	  high-­‐income	  countries.	  In	  their	  study	  of	  the	  Indian	  
biopharmaceutical	  sector,	  Wilson	  and	  Rao	  report	  that	  “[s]everal	  firms	  told	  us	  that	  they	  could	  
consider	  products	  that	  had	  only	  modest	  markets	  as	  long	  as	  they	  thought	  they	  would	  be	  able	  to	  at	  
least	  cover	  costs;	  this	  attitude	  may	  reflect	  the	  freedom	  conferred	  by	  being	  privately	  held	  (as	  
opposed	  to	  publically	  traded)	  or	  …	  state-­‐owned	  [companies]”lxxvii.	  
	  
The	  increasing	  involvement	  of	  emerging	  market	  companies	  as	  suppliers	  and	  R&D	  partners	  of	  global	  
health	  partnerships	  can	  therefore	  be	  explained	  by	  a	  combination	  of	  a	  policy	  shift	  in	  global	  health	  
governance	  towards	  greater	  pharmaceuticalization	  and	  a	  set	  of	  internal	  and	  external	  factors	  that	  can	  
create	  a	  more	  compelling	  business	  case	  for	  emerging	  market	  companies	  to	  produce	  at	  low-­‐profit	  
margins	  than	  for	  big	  pharma	  firms	  from	  Western	  Europe	  and	  the	  US.	  In	  light	  of	  the	  significant	  role	  
that	  pharmaceutical	  companies	  from	  emerging	  markets	  play	  as	  suppliers	  and	  R&D	  partners,	  their	  
weak	  representation	  on	  the	  governing	  boards	  and	  among	  the	  funders	  of	  global	  health	  partnerships	  
is	  puzzling,	  however.	  	  
	  
An	  explanation	  may	  be	  found	  in	  the	  history	  of	  global	  health	  partnerships.	  The	  ideas	  and	  values	  
underlying	  the	  rise	  of	  public-­‐private	  partnerships	  as	  instruments	  of	  governance	  are	  based	  on	  neo-­‐
liberalist	  notions	  of	  the	  role	  of	  the	  state	  as	  facilitator,	  rather	  than	  provider,	  of	  social	  policieslxxviii,	  and	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changing	  conceptions	  of	  the	  relations	  between	  public	  and	  privatelxxix,	  both	  of	  which	  have	  their	  roots	  
in	  Anglo-­‐Saxon	  schools	  of	  thoughtlxxx.	  	  Representatives	  of	  high-­‐income	  countries	  tend	  to	  be	  
significantly	  more	  numerous	  on	  the	  governing	  boards	  and	  among	  the	  funders	  of	  global	  health	  
partnerships	  than	  representatives	  from	  low-­‐	  and	  middle-­‐income	  countries,	  not	  only	  with	  regard	  to	  
representatives	  from	  the	  business	  sector.	  Among	  the	  global	  health	  partnerships	  analysed	  here,	  only	  
the	  governing	  board	  of	  GAVI	  shows	  an	  equal	  balance	  of	  representatives	  from	  high-­‐income	  countries	  
and	  low-­‐	  and	  middle-­‐income	  countries.	  At	  GFATM	  and	  DNDi,	  approximately	  one	  third	  of	  board	  
members	  are	  from	  low-­‐	  and	  middle-­‐income	  countries.	  On	  the	  governing	  boards	  of	  the	  remaining	  
global	  health	  partnerships,	  representatives	  from	  low-­‐	  and	  middle-­‐income	  countries	  make	  up	  
between	  0%	  and	  18%.	  	  
	  
Buse	  and	  Harmer	  trace	  the	  under-­‐representation	  of	  low-­‐	  and	  middle-­‐income	  countries	  in	  global	  
health	  partnerships	  back	  to	  the	  early	  days	  of	  their	  creation.	  They	  find	  that	  the	  partnership	  model	  
was	  promoted	  by	  a	  small	  group	  of	  individuals	  and	  organisations	  “from	  wealthy,	  middle-­‐class	  socio-­‐
economic	  groupings;	  none	  were	  African,	  indeed	  all	  but	  one	  were	  ‘white’,	  and	  only	  four	  were	  
female”lxxxi.	  The	  politics	  and	  power	  dynamics	  inherent	  in	  global	  health	  partnerships	  are	  evident	  also	  
in	  the	  tension	  between	  the	  terminology	  of	  ‘global’	  health	  partnerships	  and	  the	  actual	  direction	  of	  
most	  of	  their	  efforts	  towards	  low-­‐	  and	  middle-­‐income	  countries.	  Similarly,	  there	  is	  a	  mismatch	  
between	  the	  absence	  of	  emerging	  market	  companies	  on	  the	  governing	  boards	  of	  global	  health	  
partnerships	  and	  the	  language	  used	  by	  many	  of	  these	  organisations,	  which	  describes	  these	  
companies	  as	  ‘partners’.	  	  
	  
Despite	  the	  emergence	  of	  pharmaceutical	  companies	  from	  low-­‐	  and	  middle-­‐income	  countries	  as	  key	  
suppliers	  and	  R&D	  partners,	  global	  health	  partnerships	  seem	  to	  still	  be	  embedded	  in	  the	  power	  
relations	  of	  an	  aid-­‐based	  model	  of	  global	  health	  governancelxxxii.	  The	  question	  why	  these	  dynamics	  
persist	  goes	  beyond	  the	  scope	  of	  this	  article,	  but	  it	  is	  an	  important	  one.	  While	  board	  representation	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and	  provision	  of	  financial	  resources	  do	  not	  automatically	  guarantee	  influencelxxxiii,	  they	  certainly	  can	  
open	  doors	  and	  generate	  access	  to	  information	  that	  is	  important	  to	  influence	  policy.	  	  
	  
Conclusion:	  Implications	  for	  global	  health	  governance	  
	  
What	  are	  the	  implications	  of	  this	  analysis	  for	  global	  health	  governance?	  The	  concluding	  section	  
argues	  that	  the	  increasing	  involvement	  of	  pharmaceutical	  companies	  from	  emerging	  markets	  in	  
global	  health	  governance	  can	  be	  interpreted	  as	  a	  double-­‐edged	  sword.	  On	  the	  one	  hand,	  their	  
increasing	  involvement	  as	  suppliers	  of	  low-­‐cost	  pharmaceuticals	  and	  technologies	  has	  enabled	  
governments	  and	  global	  health	  partnerships	  to	  implement	  a	  key	  goal	  of	  global	  health	  policy:	  
widening	  access	  to	  pharmaceutical	  treatment	  and	  prevention.	  One	  the	  other	  hand,	  the	  analysis	  
points	  to	  a	  fundamental	  tension	  between	  this	  policy	  goal	  and	  the	  political	  economy	  of	  how	  
medicines	  and	  vaccines	  are	  developed	  and	  produced.	  	  	  
	  
Many	  of	  the	  achievements	  of	  universal	  access	  policies	  would	  not	  have	  been	  possible	  without	  
emerging	  market	  companies	  supplying	  low-­‐cost,	  high-­‐quality	  medicines	  and	  vaccines.	  For	  example,	  
the	  rapid	  scale	  up	  of	  HIV/	  AIDS	  treatment	  in	  low-­‐	  and	  middle-­‐income	  countries	  from	  a	  few	  hundred	  
thousand	  people	  in	  the	  early	  2000s	  to	  almost	  10	  millionlxxxiv	  today	  has	  been	  build	  largely	  on	  ARVs	  
produced	  by	  pharmaceutical	  companies	  from	  emerging	  marketslxxxv.	  Also,	  the	  significant	  reduction	  of	  
meningitis	  cases	  in	  Africa,	  which	  in	  2013	  was	  the	  lowest	  in	  ten	  years,	  has	  been	  attributed	  to	  the	  
introduction	  of	  a	  vaccine	  produced	  by	  an	  Indian	  company	  in	  collaboration	  with	  a	  public-­‐private	  
partnershiplxxxvi.	  
	  
Moreover,	  the	  rapid	  growth	  of	  biopharmaceutical	  innovation	  in	  emerging	  markets	  provides	  
potentially	  great	  opportunities	  for	  global	  health	  governance	  because	  the	  types	  of	  innovation	  
produced	  by	  emerging	  market	  companies	  may	  be	  well	  aligned	  with	  the	  needs	  of	  patients	  in	  low-­‐	  and	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middle-­‐income	  countries.	  	  The	  International	  Business	  literature	  has	  found	  that	  the	  low	  average	  
income	  in	  the	  domestic	  markets	  of	  emerging	  market	  companies	  has	  “spurred	  innovations	  to	  serve	  
people	  at	  the	  middle	  or	  bottom	  of	  the	  economic	  pyramid”lxxxvii.	  Many	  emerging	  market	  companies	  
seem	  to	  have	  developed	  particular	  strengths	  in	  developing	  or	  adapting	  products	  so	  as	  to	  lower	  
production	  costs	  without	  necessarily	  affecting	  qualitylxxxviii.	  In	  addition,	  many	  companies	  from	  these	  
countries	  were	  found	  to	  have	  the	  skills	  and	  customer	  knowledge	  required	  to	  make	  products	  easier	  
to	  use	  in	  the	  more	  difficult	  conditions	  of	  low-­‐	  and	  middle-­‐income	  countrieslxxxix.	  
	  
Several	  examples	  of	  such	  innovations	  by	  pharmaceutical	  companies	  from	  emerging	  markets	  exist	  
that	  have	  played	  a	  significant	  role	  in	  global	  health	  governance.	  In	  2001,	  the	  Indian	  company	  Cipla	  
introduced	  the	  first	  internationally	  recommended	  3-­‐in-­‐1	  fixed	  dose	  combination	  of	  three	  key	  ARVs	  
(Stavudine	  +	  Lamivudine	  +	  Nevirapine)	  to	  treat	  HIV/AIDS.	  The	  combination	  of	  the	  three	  ingredients	  
in	  one	  fixed-­‐dose	  treatment	  made	  it	  much	  easier	  for	  patients	  in	  low-­‐	  and	  middle-­‐income	  countries	  to	  
adhere	  to	  the	  complex	  drug	  regimen	  required	  for	  successful	  treatment.	  More	  recently,	  the	  Brazilian	  
Butantan	  Institute	  developed	  an	  innovative	  process	  to	  produce	  a	  cellular	  pertussis	  vaccine	  at	  a	  cost	  
of	  only	  US$	  0.12–0.15	  per	  dose	  compared	  with	  its	  counterpart	  costing	  US$	  8	  per	  dosexc.	  The	  
involvement	  of	  emerging	  market	  companies	  as	  R&D	  partners,	  therefore,	  may	  provide	  an	  opportunity	  
to	  access	  the	  specific	  skills	  required	  for	  the	  development	  of	  products	  that	  are	  more	  affordable	  and	  
adapted	  to	  the	  needs	  of	  users	  in	  low-­‐	  and	  middle-­‐income	  countries.	  	  
	  
The	  growing	  involvement	  of	  emerging	  market	  companies	  in	  global	  health	  governance	  therefore	  
provides	  great	  opportunities	  for	  the	  implementation	  of	  global	  access	  policies.	  Yet,	  the	  analysis	  in	  the	  
previous	  section	  of	  why	  emerging	  market	  companies	  have	  become	  involved	  in	  global	  health	  
governance	  points	  to	  the	  fragility	  of	  this	  contribution.	  It	  shows	  that	  the	  pharmaceuticalization	  of	  
global	  health	  governance	  has	  created	  great	  pressure	  on	  governments	  and	  global	  health	  partnerships	  
to	  find	  ever-­‐cheaper	  sources	  of	  medicines	  and	  vaccines.	  It	  is	  this	  price	  pressure	  that	  has	  made	  them	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turn	  to	  suppliers	  from	  emerging	  markets.	  Yet,	  while	  emerging	  market	  companies	  may	  be	  able	  to	  
produce	  at	  lower	  profit	  margins	  than	  their	  counterparts	  in	  Western	  Europe	  and	  the	  US,	  they	  too	  are	  
profit-­‐oriented	  organisations.	  The	  partnership	  language	  used	  to	  describe	  many	  of	  the	  new	  
organisations	  in	  global	  health	  can	  obscure	  the	  fact	  that	  companies	  –	  including	  emerging	  market	  
firms	  –	  engage	  in	  global	  health	  partnerships	  for	  commercial	  reasons.	  They	  are	  not	  predominantly	  
partners	  in	  global	  health	  but	  first	  and	  foremost	  business	  partners	  in	  the	  legitimate	  pursuit	  of	  profit	  
for	  their	  owners.	  It	  is	  therefore	  not	  surprising	  that	  a	  growing	  number	  of	  pharmaceutical	  companies	  
from	  emerging	  markets	  are	  responding	  to	  the	  continuous	  price	  pressure	  from	  global	  health	  
partnerships	  with	  concernxci.	  	  
	  
The	  tension	  between	  global	  health	  policy	  goals	  that	  require	  access	  to	  pharmaceuticals	  with	  
extremely	  small	  profit	  margins	  and	  the	  organisation	  of	  pharmaceutical	  supply	  by	  for-­‐profit	  
organisations	  is	  familiar	  to	  most	  scholars	  and	  practitioners	  in	  global	  health	  governance.	  In	  fact,	  the	  
creation	  of	  public-­‐private-­‐partnerships	  to	  widen	  pharmaceutical	  access	  and	  the	  use	  of	  partnership	  
language	  are	  manifestations	  of	  this	  tension.	  While	  the	  increasing	  involvement	  of	  emerging	  market	  
companies	  in	  global	  health	  partnerships	  seems	  to	  have	  mitigated	  this	  tension	  at	  first	  glance,	  a	  closer	  
look	  reveals	  that	  it	  has	  also	  brought	  further	  it	  to	  the	  fore.	  
	  
The	  tension	  between	  political	  demand	  and	  market	  demand	  for	  pharmaceuticals	  affects	  not	  only	  the	  
global	  politics	  of	  HIV/AIDSxcii	  but	  also	  the	  global	  response	  to	  a	  wide	  -­‐	  and	  growing	  -­‐	  range	  of	  other	  
diseases,	  including	  malaria	  and	  tuberculosis,	  neglected	  tropical	  diseases,	  pandemic	  influenza,	  
bioterrorism	  and,	  most	  recently,	  antibiotics.	  In	  light	  of	  the	  threat	  that	  some	  of	  these	  diseases	  pose	  
to	  public	  health	  it	  seems	  risky	  to	  base	  policy	  responses	  on	  the	  quest	  for	  ever	  cheaper	  sources	  of	  
commercial	  supply.	  Pharmaceutical	  companies	  can	  play	  a	  role	  in	  the	  development	  and	  production	  of	  
medicines	  and	  vaccines	  for	  which	  there	  is	  effective	  market	  demand,	  and	  some	  companies	  are	  willing	  
to	  produce	  at	  lower	  profit	  margins	  than	  others.	  Yet,	  for-­‐profit	  operating	  companies	  will	  not	  take	  on	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the	  costs	  and	  risks	  of	  producing	  goods	  for	  which	  the	  market	  is	  very	  small	  or	  unpredictable.	  If	  global	  
health	  governance	  is	  to	  pursue	  the	  goal	  of	  providing	  access	  to	  essential	  medicines	  and	  vaccines	  
globally	  and	  to	  sustain	  the	  successes	  already	  achieved,	  greater	  investment	  from	  the	  public	  in	  the	  
development,	  production	  and	  procurement	  of	  medicines	  and	  vaccines	  and,	  not	  least,	  greater	  public	  
investment	  in	  prevention	  is	  required.	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